PTIEのチャート
PTIEの企業情報
| symbol | PTIE |
|---|---|
| 会社名 | Pain Therapeutics Inc （ペイン・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ペイン・セラピューティクス(Pain Therapeutics Inc.)は薬物の開発に従事するバイオ製薬会社。同社は実施中の臨床プログラムの４つの製品候補を持つ。その中には、REMOXY、転移性黒色腫患者を対象とした放射標識モノクローナル抗体、乱用防止ヒドロモルフォン、乱用防止ヒドロコドンがある。血友病患者を対象とした新治療法の研究を行っている。同社はKing Pharmaceuticals Inc. (King)と提携契約を締結して、REMOXYとその他オピオイド鎮痛薬の開発と商業化を行う。同社はKingと共同でREMOXYの新薬申請(NDA)提出と第3相臨床プログラムを管理する。また、同社は腫瘍学と血液学分野の薬物候補を開発している。同社は腫瘍学と血液学分野の薬物候補の商業権全部を所有する。平成22年12月31日現在、同社はカリフォルニア州サンマテオで約30700平方フィートのスペースをリースし、サンマテオで業務の全てを運営している。 ペイン・セラピュ―ティックスは米国のバイオ医薬品企業。薬剤候補は経口カプセル剤の鎮痛剤「レモクシ―(REMOXY)」。「レモクシ―」はオキシコドンを含むゼラチン・カプセル剤で、1日に2回の服用で長時間作用する。同社は、ファイザ―の子会社であるキング・ファ―マシュ―ティカルズと新薬開発を提携する。本社はテキサス州オ―スティン。 Develops novel drugs |
| 本社所在地 | 7801 N. Capital of Texas Highway Suite 260 Austin TX 78731 USA |
| 代表者氏名 | Remi Barbier レミバルビエ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 512-501-2444 |
| 設立年月日 | 35916 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | － |
| url | www.paintrials.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ptie |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.57900 |
| 終値（lastsale） | 1.27 |
| 時価総額（marketcap） | 21741511 |
| 時価総額 | 時価総額（百万ドル） 22.08390 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 12.47590 |
| 当期純利益 | 当期純利益（百万ドル） -9.62000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pain Therapeutics Inc. revenues was not reported. Net loss decreased 33% to $4.6M. Lower net loss reflects Other Research_Develop decrease of 52% to $1.9M (expense) Other General_Admin decrease of 18% to $1.3M (expense) Stock-Based Compensation Expense decrease of 11% to $832K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.06 to -$0.68. |
PTIEのテクニカル分析
PTIEのニュース
Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. 2019/03/27 12:30:00 Benzinga
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NASDAQ: PTIE ), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company's strategic focus on drug development for neurodegenerative diseases, such as Alzheimer's disease. Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. "A new Company name is part of a larger rebranding effort around neurodegenerative diseases, such as Alzheimer's disease," said Remi Barbier, Chairman, President & CEO of Cassava Sciences. "One thing that won't change is our focus on developing potential breakthrough innovations and an unwavering dedication to improve people's lives. This emphasis has characterized our history and remains core to our strategy today." Cassava Sciences is in Phase II clinical testing with a new drug candidate to treat patients with Alzheimer's disease. The Company's Phase II study is being conducted with scientific and financial support from the National Institutes of Health (NIH).
Pain Therapeutics Announces Name Change to Cassava Sciences, Inc. 2019/03/27 12:30:00 Benzinga
AUSTIN, Texas, March 27, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NASDAQ: PTIE ), a drug development company, announced a company name change to Cassava Sciences, Inc., effective immediately. The new name was chosen to better reflect the Company's strategic focus on drug development for neurodegenerative diseases, such as Alzheimer's disease. Beginning March 28, 2019, Cassava Sciences will trade on NASDAQ under the new ticker symbol: SAVA. "A new Company name is part of a larger rebranding effort around neurodegenerative diseases, such as Alzheimer's disease," said Remi Barbier, Chairman, President & CEO of Cassava Sciences. "One thing that won't change is our focus on developing potential breakthrough innovations and an unwavering dedication to improve people's lives. This emphasis has characterized our history and remains core to our strategy today." Cassava Sciences is in Phase II clinical testing with a new drug candidate to treat patients with Alzheimer's disease. The Company's Phase II study is being conducted with scientific and financial support from the National Institutes of Health (NIH).